HK Stock Market Move | DALIPAL HLDG (01921) resumes trading, up more than 5%, introduces Saudi strategic investors to advance Middle East projects.
Dali Group (01921) resumed trading and rose by over 5%, as of the time of writing, up 5.29% to 8.36 Hong Kong dollars, with a total turnover of 81.103 million Hong Kong dollars.
DALIPAL HLDG (01921) resumed trading with an increase of over 5%, rising by 5.29% to 8.36 Hong Kong dollars, with a turnover of 8.11 million Hong Kong dollars as of the time of writing.
In terms of news, DALIPAL HLDG announced the sale of 40% equity in Dalipu International to Zumar, a strategic investment and development company in Saudi Arabia, for a total consideration of 3 million Saudi Riyal. After completion, the company and Zumar will respectively hold 60% and 40% of Dalipu International, and both parties agree to increase the share capital of Dalipu International to $150 million to $240 million initially based on their respective holdings, to provide partial funding for the first phase of the total project cost. The company is expected to contribute up to $144 million.
The remaining amount of the total project cost will be funded by third-party debt financing, shareholder loans, or shareholder cash contributions (as agreed from time to time). The project will be constructed in two phases, with a total designed production capacity of 1.1 million tons per year. The first phase of the project is expected to involve an investment of $600 million.
Related Articles
.png)
HK Stock Market Move | SINO BIOPHARM(01177) rises more than 4%, management is optimistic about the prospects of VIIa being included in insurance coverage. The drug is developed by its subsidiary, Zhongda Tianqing.

HK Stock Market Move | IMMUNEONCO-B(01541) rose by more than 10% in early trading. IMM01 has been approved for clinical trials for the treatment of atherosclerosis.

Furui: Lower target price of LAOPU GOLD (06181) to 981 Hong Kong dollars. High gold prices suppress gross profit.
HK Stock Market Move | SINO BIOPHARM(01177) rises more than 4%, management is optimistic about the prospects of VIIa being included in insurance coverage. The drug is developed by its subsidiary, Zhongda Tianqing.
.png)
HK Stock Market Move | IMMUNEONCO-B(01541) rose by more than 10% in early trading. IMM01 has been approved for clinical trials for the treatment of atherosclerosis.

Furui: Lower target price of LAOPU GOLD (06181) to 981 Hong Kong dollars. High gold prices suppress gross profit.

RECOMMEND

Patent Cliff Looms As Pharmaceutical Sector Prepares For A New Round Of Asset Competition
10/01/2026

Goldman Sachs Remains Bullish On China Equities: AI And Overseas Expansion To Drive Earnings, MSCI China Seen Rising 20% In 2026
10/01/2026

“A+H” Popularity Continues As Multiple A‑Share Companies Announce Hong Kong Listings At The Start Of The Year
10/01/2026


